FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968870147> ?p ?o ?g. }

• W1968870147 endingPage "2666" @default.
• W1968870147 startingPage "2659" @default.
• W1968870147 abstract "To assess the effects of arginine vasopressin (AVP) on hemodynamic, clinical, and laboratory variables and to determine its adverse side effects in advanced vasodilatory shock.Retrospective study.A total of 316 patients.AVP infusion (4 units/hr).Cardiocirculatory, laboratory, and clinical variables were evaluated before, 0.5, 1, 4, 12, 24, 48, and 72 hrs after administration of AVP. AVP increased mean arterial pressure, systemic vascular resistance, and stroke volume index. Heart rate, central venous pressure, mean pulmonary arterial pressure, norepinephrine, milrinone, and epinephrine requirements decreased. There was no difference in the hemodynamic response between patients with septic shock, postcardiotomy shock, or systemic inflammatory response syndrome. Cardiac index decreased in 41.1% of patients during AVP treatment. In patients with hyperdynamic circulation before AVP, cardiac index decreased, whereas it remained uncharged or tended to increase in patients with normodynamic or hypodynamic circulation. During the course of AVP treatment, liver enzymes (28.5% of patients) and total bilirubin concentrations (69.3% of patients) increased, whereas platelet count decreased (73.4% of patients). Simultaneous hemofiltration significantly contributed to the decrease in platelet count (p < .001) and increase in bilirubin (p < .001). Whereas patients with an increase in bilirubin were more likely to die, a decrease in cardiac index or platelet count and an increase in liver enzymes did not affect mortality. Systemic inflammatory response syndrome as admission diagnosis, a high degree of multiple organ dysfunction, and norepinephrine requirements of >0.5 microg x kg x min before AVP treatment were independent risk factors for death from advanced vasodilatory shock treated with AVP. If norepinephrine dosages exceeded 0.6 microg x kg x min before AVP treatment, a substantial increase in mortality occurred.Supplementary AVP infusion improved cardiocirculatory function in advanced vasodilatory shock, but an increase in liver enzymes and bilirubin, and a decrease in platelet count occurred during AVP therapy, particularly during simultaneous hemofiltration. Initiation of AVP infusion before norepinephrine requirements exceeding 0.6 microg x kg x min may improve outcome." @default.
• W1968870147 created "2016-06-24" @default.
• W1968870147 creator A5004500883 @default.
• W1968870147 creator A5007099379 @default.
• W1968870147 creator A5014624933 @default.
• W1968870147 creator A5037866671 @default.
• W1968870147 creator A5038125897 @default.
• W1968870147 creator A5038859254 @default.
• W1968870147 creator A5045764223 @default.
• W1968870147 creator A5046761989 @default.
• W1968870147 creator A5061283393 @default.
• W1968870147 creator A5072011414 @default.
• W1968870147 creator A5083586698 @default.
• W1968870147 creator A5085125500 @default.
• W1968870147 date "2005-11-01" @default.
• W1968870147 modified "2023-10-17" @default.
• W1968870147 title "Arginine vasopressin in 316 patients with advanced vasodilatory shock*" @default.
• W1968870147 cites W1968590837 @default.
• W1968870147 cites W1969994160 @default.
• W1968870147 cites W1972308512 @default.
• W1968870147 cites W2004095374 @default.
• W1968870147 cites W2004536137 @default.
• W1968870147 cites W2011416633 @default.
• W1968870147 cites W2028546766 @default.
• W1968870147 cites W2029062063 @default.
• W1968870147 cites W2030319092 @default.
• W1968870147 cites W2052529172 @default.
• W1968870147 cites W2058346805 @default.
• W1968870147 cites W2059982374 @default.
• W1968870147 cites W2063162754 @default.
• W1968870147 cites W2067338751 @default.
• W1968870147 cites W2077234592 @default.
• W1968870147 cites W2080335666 @default.
• W1968870147 cites W2082246284 @default.
• W1968870147 cites W2092576934 @default.
• W1968870147 cites W2092757939 @default.
• W1968870147 cites W2096390947 @default.
• W1968870147 cites W2102372841 @default.
• W1968870147 cites W2102676019 @default.
• W1968870147 cites W2110944531 @default.
• W1968870147 cites W2127815897 @default.
• W1968870147 cites W2134771022 @default.
• W1968870147 cites W2143650227 @default.
• W1968870147 cites W2147352702 @default.
• W1968870147 cites W2148981533 @default.
• W1968870147 cites W2158301788 @default.
• W1968870147 cites W2418923184 @default.
• W1968870147 cites W2468730578 @default.
• W1968870147 cites W2599527603 @default.
• W1968870147 cites W344652806 @default.
• W1968870147 cites W4247943214 @default.
• W1968870147 doi "https://doi.org/10.1097/01.ccm.0000186749.34028.40" @default.
• W1968870147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16276194" @default.
• W1968870147 hasPublicationYear "2005" @default.
• W1968870147 type Work @default.
• W1968870147 sameAs 1968870147 @default.
• W1968870147 citedByCount "181" @default.
• W1968870147 countsByYear W19688701472012 @default.
• W1968870147 countsByYear W19688701472013 @default.
• W1968870147 countsByYear W19688701472015 @default.
• W1968870147 countsByYear W19688701472016 @default.
• W1968870147 countsByYear W19688701472017 @default.
• W1968870147 countsByYear W19688701472018 @default.
• W1968870147 countsByYear W19688701472019 @default.
• W1968870147 countsByYear W19688701472020 @default.
• W1968870147 countsByYear W19688701472021 @default.
• W1968870147 countsByYear W19688701472022 @default.
• W1968870147 countsByYear W19688701472023 @default.
• W1968870147 crossrefType "journal-article" @default.
• W1968870147 hasAuthorship W1968870147A5004500883 @default.
• W1968870147 hasAuthorship W1968870147A5007099379 @default.
• W1968870147 hasAuthorship W1968870147A5014624933 @default.
• W1968870147 hasAuthorship W1968870147A5037866671 @default.
• W1968870147 hasAuthorship W1968870147A5038125897 @default.
• W1968870147 hasAuthorship W1968870147A5038859254 @default.
• W1968870147 hasAuthorship W1968870147A5045764223 @default.
• W1968870147 hasAuthorship W1968870147A5046761989 @default.
• W1968870147 hasAuthorship W1968870147A5061283393 @default.
• W1968870147 hasAuthorship W1968870147A5072011414 @default.
• W1968870147 hasAuthorship W1968870147A5083586698 @default.
• W1968870147 hasAuthorship W1968870147A5085125500 @default.
• W1968870147 hasConcept C126322002 @default.
• W1968870147 hasConcept C139940330 @default.
• W1968870147 hasConcept C164705383 @default.
• W1968870147 hasConcept C178853913 @default.
• W1968870147 hasConcept C2776370428 @default.
• W1968870147 hasConcept C2776452961 @default.
• W1968870147 hasConcept C2777628635 @default.
• W1968870147 hasConcept C2777953023 @default.
• W1968870147 hasConcept C2778384902 @default.
• W1968870147 hasConcept C2778514916 @default.
• W1968870147 hasConcept C2779065481 @default.
• W1968870147 hasConcept C2781300812 @default.
• W1968870147 hasConcept C31861589 @default.
• W1968870147 hasConcept C35207712 @default.
• W1968870147 hasConcept C42219234 @default.
• W1968870147 hasConcept C513476851 @default.
• W1968870147 hasConcept C58245268 @default.

• next